INVOKANA^® (canagliflozin) protects against renal events in type 2 diabetes²

Prescribing Information can be found under Useful Links

Invokana^®(canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

As monotherapy when metformin is considered inappropriate due to intolerance or contraindications
In addition to other medicinal products for the treatment of diabetes

For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, please refer to section 4.4, 4.5 and 5.1 of the Invokana SmPC.

The addition of Invokana to standard of care resulted in significant reductions in diabetic kidney disease (DKD) progressions vs placebo ^4,11

CANVAS Program⁵

The CANVAS Program consisted of two double-blind randomised trials, that assessed canagliflozin vs placebo in participants with T2D who were at high risk of CV events.

CREDENCE⁴

CREDENCE is the first study involving an SGLT2 inhibitor, dedicated to renal outcome patients with T2D.

Renal endpoint – relative reduction of uACR (urinary albumin-creatinine ratio)

CANVAS Program

(95% CI, 16-20; no p value given; geometric mean of UACR) on average during follow-up vs placebo ¹¹

CREDENCE

(95% CI, 26-35; no p value given; geometric mean of UACR) on average during follow-up vs placebo ⁴

Invokana-Diagram-8

CANVAS Program

47%(HR, 0.53; 95% CI, 0.33-0.84; nominal significance) NNT (3.0 years): 97 (95% CI, not stated)¹¹

CREDENCE

34%(HR, 0.66; 95% CI, 0.53-0.81; P<0.001) NNT (2.5 years): NNT (3.0 years): 97 (95% CI, not stated) 28 (95% CI, 19-54)⁴

-47%-Red-Circle

-34%-Blue-Circle

Abbreviations:

CI – Confidence Interval
ESKD – End Stage Kidney
Disease
HR – Hazard Ratio
NNT – Number Need to Treat
RRR - Relative Risk Reduction

Invokana could delay progression to dialysis by up to 13 years ^4,12

Based on long term extrapolation from CREDENCE data, using canagliflozin 100mg daily in addition to standard of care

Invokana-Diagram-10

PP-IN-UK-0236 July 2023

INVOKANA® (canagliflozin) protects against renal events in type 2 diabetes2

The addition of Invokana to standard of care resulted in significant reductions in diabetic kidney disease (DKD) progressions vs placebo 4,11

CANVAS Program5

CREDENCE4

Renal endpoint – relative reduction of uACR (urinary albumin-creatinine ratio)

CANVAS Program

CREDENCE

CANVAS Program

CREDENCE

Invokana could delay progression to dialysis by up to 13 years 4,12

INVOKANA^® (canagliflozin) protects against renal events in type 2 diabetes²

The addition of Invokana to standard of care resulted in significant reductions in diabetic kidney disease (DKD) progressions vs placebo ^4,11

CANVAS Program⁵

CREDENCE⁴

Invokana could delay progression to dialysis by up to 13 years ^4,12